Monoclonal antibodies (mAbs) offer a treatment option for individuals with severe COVID-19
and are especially important in high-risk individuals where vaccination is not an option …

Abstract COVID-19, caused by SARS-CoV-2, is the most consequential pandemic of this
century. Since the outbreak in late 2019, animal models have been playing crucial roles in …

Abstract Background The Omicron SARS-CoV-2 variant is responsible for a major wave of
COVID-19, with record case counts reflecting high transmissibility and escape from prior …

Objective Immunocompromised patients have an increased risk of a severe form of COVID-
19. The clinical efficacy of the tixagevimab/cilgavimab monoclonal antibody combination as …

Summary Background SARS-CoV-2-specific adaptive immunity more than 1 year after initial
infection has not been well characterised. The aim of this study was to investigate the …

Background: The combined impact of immunity and SARS-CoV-2 variants on viral kinetics
during infections has been unclear. Methods: We characterized 1,280 infections from the …

The rapid emergence of SARS-CoV-2 variants challenges vaccination strategies. Here, we
collected 201 serum samples from persons with a single infection or multiple vaccine …

Multiple monoclonal antibodies have been shown to be effective for both prophylaxis and
therapy for SARS-CoV-2 infection. Here we aggregate data from randomized controlled …

Objectives Vaccine effectiveness against transmission (VET) of SARS-CoV-2-infection can
be estimated from secondary attack rates observed during contact tracing. We estimated …

ABSTRACT SARS-CoV-2 Omicron variants contain many mutations in its spike receptor-
binding domain, the target of all authorized monoclonal antibodies (MAbs). Determining the …